(CercleFinance.com) – The Ose Immunotherapeutics share gained almost 6% in Paris, benefiting from a positive analysis by Invest Securities which maintained its buy opinion on the share and its price target of 14.3E.
The analyst believes that if the Biotech sector does not escape the downward spiral, in a particularly tense macroeconomic context, ‘some companies stand out thanks to a dense newsflow, which helps to fuel the momentum while waiting for better days. OSE Immuno is one of the listed companies with the richest pipelines, which promotes newsflow,’ says the analyst.
‘Although the announcements do not always translate into the share price, it nevertheless remains the appointment created with investors attesting to the progress of the company and the good orientation of both strategy and results. The month of June proved to be particularly rich in announcements of different types’, adds the broker.